Literature DB >> 19735092

Hereditary parkinsonism: Parkinson disease look-alikes--an algorithm for clinicians to "PARK" genes and beyond.

Christine Klein1, Susanne A Schneider, Anthony E Lang.   

Abstract

In the past decade, a number of genetic causes of parkinsonism have been identified. As a consequence, clinicians have to consider an increasing range of differential diagnoses when confronted with a patient with parkinsonism with a positive family history. While well-established monogenic forms with PARK acronyms have been reviewed extensively, less emphasis has been placed on other inherited conditions that may also present with signs of parkinsonism or even mimic idiopathic Parkinson's disease clinically. In this review, we focus on three different scenarios in patients with an overall early age of onset of parkinsonism: (i) atypical features in patients with mutations in one of the "PARK" genes; (ii) classical parkinsonism due to mutations in "other than-PARK" genes or yet other genes where parkinsonism may be a well-recognized, concomitant, or even an isolated feature; (iii) atypical parkinsonism in other genetic disorders which are, however, typically characterized by features other than parkinsonism. Atypical features in patients from Group I include, for example, a slower disease course (PARK2, PARK6, PARK7) or dementia (PARK1/4, PARK14). Conditions in Group II have been designated by a DYT or SCA acronym (for example, DYT5 or SCA3) and also include patients with heterozygous GBA mutations, mitochondrial gene mutations. Group III comprises mutations in the FMR1, MAPT, GRN, ATP7B, PANK2, FBXO7, CHAC, FTL1, Huntingtin, JPH3 genes, and a number of even rarer, miscellaneous conditions. (c) 2009 Movement Disorder Society.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19735092     DOI: 10.1002/mds.22675

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  17 in total

1.  Effects of parkinsonism on health status in welding exposed workers.

Authors:  Rachel C Harris; Jessica I Lundin; Susan R Criswell; Angela Hobson; Laura M Swisher; Bradley A Evanoff; Harvey Checkoway; Brad A Racette
Journal:  Parkinsonism Relat Disord       Date:  2011-07-02       Impact factor: 4.891

Review 2.  Fragile X-associated tremor/ataxia syndrome: phenotypic comparisons with other movement disorders.

Authors:  Erin E Robertson; Deborah A Hall; Andrew R McAsey; Joan A O'Keefe
Journal:  Clin Neuropsychol       Date:  2016-08       Impact factor: 3.535

3.  Ataxin-3 deubiquitination is coupled to Parkin ubiquitination via E2 ubiquitin-conjugating enzyme.

Authors:  Thomas M Durcan; Maria Kontogiannea; Nathalie Bedard; Simon S Wing; Edward A Fon
Journal:  J Biol Chem       Date:  2011-11-11       Impact factor: 5.157

Review 4.  What is the role of genetic testing in movement disorders practice?

Authors:  Susanne A Schneider; Christine Klein
Journal:  Curr Neurol Neurosci Rep       Date:  2011-08       Impact factor: 5.081

5.  Pilot study: peripheral biomarkers for diagnosing sporadic Parkinson's disease.

Authors:  Edna Grünblatt; Sonja Zehetmayer; Christian P Jacob; Thomas Müller; Wolfgang H Jost; Peter Riederer
Journal:  J Neural Transm (Vienna)       Date:  2010-11-11       Impact factor: 3.575

6.  Clinical approach to Parkinson's disease: features, diagnosis, and principles of management.

Authors:  João Massano; Kailash P Bhatia
Journal:  Cold Spring Harb Perspect Med       Date:  2012-06       Impact factor: 6.915

Review 7.  Parkinsonism due to mutations in PINK1, parkin, and DJ-1 and oxidative stress and mitochondrial pathways.

Authors:  Mark R Cookson
Journal:  Cold Spring Harb Perspect Med       Date:  2012-09-01       Impact factor: 6.915

8.  The entity of parkinsonism and associated lipomatosis.

Authors:  Maria Stamelou; Una-Marie Sheerin; Nicholas Wood; Kailash P Bhatia
Journal:  Neurology       Date:  2014-10-01       Impact factor: 9.910

9.  Family-based association analysis of the MAPT gene in Parkinson disease.

Authors:  K S Wang; J E Mullersman; X F Liu
Journal:  J Appl Genet       Date:  2010       Impact factor: 2.653

10.  Rotenone, paraquat, and Parkinson's disease.

Authors:  Caroline M Tanner; Freya Kamel; G Webster Ross; Jane A Hoppin; Samuel M Goldman; Monica Korell; Connie Marras; Grace S Bhudhikanok; Meike Kasten; Anabel R Chade; Kathleen Comyns; Marie Barber Richards; Cheryl Meng; Benjamin Priestley; Hubert H Fernandez; Franca Cambi; David M Umbach; Aaron Blair; Dale P Sandler; J William Langston
Journal:  Environ Health Perspect       Date:  2011-01-26       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.